Literature DB >> 20863228

Artemisinin‐induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure.

Franka Teuscher1, Michelle L Gatton, Nanhua Chen, Jennifer Peters, Dennis E Kyle, Qin Cheng.   

Abstract

BACKGROUND: Despite the remarkable activity of artemisinin and its derivatives, monotherapy with these agents has been associated with high rates of recrudescence. The temporary arrest of the growth of ring-stage parasites (dormancy) after exposure to artemisinin drugs provides a plausible explanation for this phenomenon.
METHODS: Ring-stage parasites of several Plasmodium falciparum lines were exposed to different doses of dihydroartemisinin (DHA) alone or in combination with mefloquine. For each regime, the proportion of recovering parasites was determined daily for 20 days.
RESULTS: Parasite development was abruptly arrested after a single exposure to DHA, with some parasites being dormant for up to 20 days. Approximately 50% of dormant parasites recovered to resume growth within the first 9 days. The overall proportion of parasites recovering was dose dependent, with recovery rates ranging from 0.044% to 1.313%. Repeated treatment with DHA or with DHA in combination with mefloquine led to a delay in recovery and an approximately 10-fold reduction in total recovery. Strains with different genetic backgrounds appeared to vary in their capacity to recover.
CONCLUSIONS: These results imply that artemisinin-induced arrest of growth occurs readily in laboratory-treated parasites and may be a key factor in P. falciparum malaria treatment failure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20863228      PMCID: PMC2949454          DOI: 10.1086/656476

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

Review 1.  Delaying antimalarial drug resistance with combination chemotherapy.

Authors:  N J White
Journal:  Parassitologia       Date:  1999-09

2.  Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study.

Authors:  F Nosten; M van Vugt; R Price; C Luxemburger; K L Thway; A Brockman; R McGready; F ter Kuile; S Looareesuwan; N J White
Journal:  Lancet       Date:  2000-07-22       Impact factor: 79.321

3.  Artemisinin for treatment of uncomplicated falciparum malaria: is there a place for monotherapy?

Authors:  P T Giao; T Q Binh; P A Kager; H P Long; N Van Thang; N Van Nam; P J de Vries
Journal:  Am J Trop Med Hyg       Date:  2001-12       Impact factor: 2.345

4.  Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens.

Authors:  M B Hoshen; K Na-Bangchang; W D Stein; H Ginsburg
Journal:  Parasitology       Date:  2000-09       Impact factor: 3.234

5.  Short-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon.

Authors:  Steffen Borrmann; Ayola A Adegnika; Michel A Missinou; Ronald K Binder; Saadou Issifou; Andreas Schindler; Pierre-Blaise Matsiegui; Jürgen F J Kun; Sanjeev Krishna; Bertrand Lell; Peter G Kremsner
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

6.  Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism.

Authors:  Benoit Witkowski; Joel Lelièvre; María José López Barragán; Victor Laurent; Xin-zhuan Su; Antoine Berry; Françoise Benoit-Vical
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

7.  Human malaria parasites in continuous culture.

Authors:  W Trager; J B Jensen
Journal:  Science       Date:  1976-08-20       Impact factor: 47.728

Review 8.  M. tuberculosis persistence, latency, and drug tolerance.

Authors:  James E Gomez; John D McKinney
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

9.  Randomised efficacy and safety study of two 3-day artesunate rectal capsule/mefloquine regimens versus artesunate alone for uncomplicated malaria in Ecuadorian children.

Authors:  E A Gomez; M H Jurado; N Cambon
Journal:  Acta Trop       Date:  2003-12       Impact factor: 3.112

10.  Artesunate with mefloquine at various intervals for non-severe Plasmodium falciparum malaria.

Authors:  Le Q Hung; Peter J de Vries; Tran Q Binh; Phan T Giao; Nguyen V Nam; R Holman; Piet A Kager
Journal:  Am J Trop Med Hyg       Date:  2004-08       Impact factor: 2.345

View more
  109 in total

1.  Phytohormones, Isoprenoids, and Role of the Apicoplast in Recovery from Dihydroartemisinin-Induced Dormancy of Plasmodium falciparum.

Authors:  Marvin Duvalsaint; Dennis E Kyle
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 2.  Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum.

Authors:  Connor O'Brien; Philipp P Henrich; Neha Passi; David A Fidock
Journal:  Curr Opin Infect Dis       Date:  2011-12       Impact factor: 4.915

3.  An epigenetic antimalarial resistance mechanism involving parasite genes linked to nutrient uptake.

Authors:  Paresh Sharma; Kurt Wollenberg; Morgan Sellers; Kayvan Zainabadi; Kevin Galinsky; Eli Moss; Wang Nguitragool; Daniel Neafsey; Sanjay A Desai
Journal:  J Biol Chem       Date:  2013-05-28       Impact factor: 5.157

4.  Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Authors:  Katherine Winter; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

5.  Microbiology: Malaria runs rings round artemisinin.

Authors:  Jeremy Burrows
Journal:  Nature       Date:  2015-04-15       Impact factor: 49.962

6.  Altered temporal response of malaria parasites determines differential sensitivity to artemisinin.

Authors:  Nectarios Klonis; Stanley C Xie; James M McCaw; Maria P Crespo-Ortiz; Sophie G Zaloumis; Julie A Simpson; Leann Tilley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

7.  Viability Screen of LOPAC1280 Reveals Tyrosine Kinase Inhibitor Tyrphostin A9 as a Novel Partner Drug for Artesunate Combinations To Target the Plasmodium falciparum Ring Stage.

Authors:  Sarah E L Ang; Esther H N Tan; Jie Xin Tong; Kevin S W Tan
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 8.  Malaria biology and disease pathogenesis: insights for new treatments.

Authors:  Louis H Miller; Hans C Ackerman; Xin-zhuan Su; Thomas E Wellems
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

9.  Artemisinin resistance in Plasmodium falciparum: A process linked to dormancy?

Authors:  Qin Cheng; Dennis E Kyle; Michelle L Gatton
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-01-27       Impact factor: 4.077

10.  Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model.

Authors:  Juliana M Sá; Sarah R Kaslow; Michael A Krause; Viviana A Melendez-Muniz; Rebecca E Salzman; Whitney A Kite; Min Zhang; Roberto R Moraes Barros; Jianbing Mu; Paul K Han; J Patrick Mershon; Christine E Figan; Ramoncito L Caleon; Rifat S Rahman; Tyler J Gibson; Chanaki Amaratunga; Erika P Nishiguchi; Kimberly F Breglio; Theresa M Engels; Soundarapandian Velmurugan; Stacy Ricklefs; Judith Straimer; Nina F Gnädig; Bingbing Deng; Anna Liu; Ababacar Diouf; Kazutoyo Miura; Gregory S Tullo; Richard T Eastman; Sumana Chakravarty; Eric R James; Kenneth Udenze; Suzanne Li; Daniel E Sturdevant; Robert W Gwadz; Stephen F Porcella; Carole A Long; David A Fidock; Marvin L Thomas; Michael P Fay; B Kim Lee Sim; Stephen L Hoffman; John H Adams; Rick M Fairhurst; Xin-Zhuan Su; Thomas E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.